Obalon Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Obalon Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 52% to $1,588,000. The net income raised on -$12,334,000 and profit margin reached -777%. Total operating expenses were $11,226,000.
Profit Margin
| 2014 | 3.53M | -9.89M | -279.46% |
|---|---|---|---|
| 2015 | 4.03M | -15.55M | -385.17% |
| 2016 | 3.39M | -20.46M | -603.21% |
| 2017 | 9.91M | -34.76M | -350.67% |
| 2018 | 9.10M | -37.38M | -410.72% |
| 2019 | 3.28M | -23.67M | -721.61% |
| 2020 | 1.58M | -12.33M | -776.7% |
OBLN Income Statement (2014 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue | 1.58M | 3.28M | 9.10M | 9.91M | 3.39M | 4.03M | 3.53M |
Cost of revenue | 1.00M | 2.95M | 5.42M | 4.82M | 2.80M | 2.50M | 2.91M |
Gross profit | 584K | 331K | 3.67M | 5.08M | 584K | 1.53M | 627K |
Operating exp. | |||||||
Research and development | 2.45M | 6.89M | 10.69M | 10.64M | 9.87M | 12.97M | 5.76M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 11.22M | 23.56M | 40.64M | 39.47M | 20.08M | 16.46M | 10.46M |
Operating income | -10.64M | -23.23M | -36.96M | -34.39M | -19.50M | -14.93M | -9.84M |
Other income (expenses), net | -1.69M | -446K | -415K | -374K | -962K | -624K | -50K |
Income before tax | -12.33M | -23.67M | -37.38M | -34.76M | -20.46M | -15.55M | -9.89M |
Income tax expense | -1.69M | -446K | -415K | -374K | -962K | -624K | -50K |
Net income | -12.33M | -23.67M | -37.38M | -34.76M | -20.46M | -15.55M | -9.89M |
Earnings per share | |||||||
Basic EPS | -1.59 | -5.03 | -19.64 | -20.8 | -48.48 | -17.23 | -10.21 |
Diluted EPS | -1.59 | -5.03 | -19.64 | -20.8 | -48.48 | -17.23 | -10.21 |
| Data source | Data source | Data source | Data source | Data source |